Abstract
The association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregnancy and the risk of major birth defects was studied by researchers at the Statens Serum Institut, Copenhagen, Denmark.
Highlights
The association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregnancy and the risk of major birth defects was studied by researchers at the Statens Serum Institut, Copenhagen, Denmark
Cases of birth defects diagnosed within the first year of life following fetal exposure to AEDs were identified through the National Patient Registry, Jan 1996 through March 2009
Of 1532 infants exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam during the first trimester, 49 (3.2%) were diagnosed with a major birth defect compared to 2.4% of unexposed infants
Summary
MAJOR BIRTH DEFECTS AND NEWER ANTIEPILEPTIC DRUGS The association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregnancy and the risk of major birth defects was studied by researchers at the Statens Serum Institut, Copenhagen, Denmark. Cases of birth defects diagnosed within the first year of life following fetal exposure to AEDs were identified through the National Patient Registry, Jan 1996 through March 2009.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
